[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NYU Langone Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":553},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,232,0,25,[9,43,68,92,113,137,155,186,209,230,250,272,290,311,328,348,374,396,414,434,452,472,490,510,531],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053434","person-centered-quality-measurement-and-management-in-a-system-for-addictions-treatment-in-new-york-state-project-3-100053434",false,"NCT06408233","Person-Centered Quality Measurement and Management in a System for Addictions Treatment in New York State (Project 3)","Person-Centered Quality Measurement and Management (QM2) in a System for Addictions Treatment in New York State (Project 3)","Inclusion Criteria:\n\n* Individuals 18 years of age, and older\n* Clients and clinicians of people attending substance use treatment programs in New York State with Opioid Use Disorder in the time interval 2020-2027\n\nExclusion Criteria:\n\n* There are no exclusion criteria related to sex\u002Fgender to increase the generalizability of the findings. Children will not be included in this study because the treatment system mostly includes adults.",true,"ALL","18 Years","64 Years",{"count":22,"type":23},35,"ESTIMATED","INTERVENTIONAL",[26],"NA","The goal of this study is to implement Opioid Use Disorder Quality Measurement and Management (OUD-QM2) strategy by the Office of Addiction Services and Supports (OASAS) to drive change and improve treatment practices. Through a concurrent mixed methods approach that iteratively examines quantitative and qualitative data to inform the process, the investigators will examine the effects of the strategy on stakeholders-PWUD\u002Fpatients, families, and providers-and outcomes. This comprehensive approach will allow for a \"global\" view of the perceived effects of the OUD-QM2 strategy for all stakeholders while allowing us to use administrative data to test the effects of the strategy on patient outcomes. Through qualitative interviews and focus groups conducted in years 1, 3, and 5 of the phase, the investigators will derive information from stakeholders about their perceptions and use of the quality measures. Through surveys conducted with all clinics, the investigators will elicit data on changes in provider use of quality measures, clinical practice, and use of measures for incentive-based contracting. Finally, the investigators will conduct a stepped wedge trial to examine the effects of performance coaching that guides clinics on use of the quality measures for clinical practice improvement. The trial will also benefit from a treatment as usual (TAU) condition of clinics not participating in the trial to examine secular trends in patient outcomes across the period of the OASAS QM2 strategy rollout. The overall aim is to build and test a science-based OUD-QM2 strategy for person-centered treatment.",[29],"Health Services Research","RECRUITING","2026-07-09",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2025-08-01",{"date":38,"type":23},"2028-12-01",{"name":40,"class":41},"NYU Langone Health","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":18,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":24,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100053740","high-protein-plus-resistance-training-in-glucagon-like-peptide-1-receptor-agonist-users-hustle-100053740","NCT07700030","High-protein plUs reSistance Training in gLucagon-like pEptide 1 Receptor Agonist Users (HUSTLE)","Inclusion Criteria:\n\n* Age 30- 60 years\n* BMI 27.0-37.0 kg\u002Fm² at screening\n* English speaking (at this time, MyNetDiary, a food-logging app used for tracking protein-intake, is only set up for English, and our RDN is only capable of providing nutritional counseling in English)\n* Received a prescription for tirzepatide, a second-generation oral or injectable dual GIP\u002FGLP-1 receptor agonist (Zepbound\u002FMounjaro) that is FDA-approved for obesity; and\n\n  * Has not yet started tirzepatide and agrees to complete a 4-week run-in period at the initial dose with \\\u003C3% weight loss from baseline; OR\n  * Has initiated tirzepatide and is within the first 4 weeks at the initial dose with \\\u003C3% weight loss from pre-treatment baseline.\n* On a stable regimen for major chronic conditions (e.g., antihypertensives, lipid-lowering agents, oral antidiabetics, hypothyroidism) for ≥ 8 weeks prior to enrollment.\n* Willing and able to:\n\n  * (i) Receive high-protein diet counseling and attempt to achieve \\~2.5 g\u002Fkg FFM \u002Fday protein;\n  * (ii) Attend scheduled nutrition telehealth visits with an RDN;\n  * (iii) Medically cleared for moderate-intensity resistance training 2 days\u002Fweek (no condition that would preclude safe participation in either diet-only or diet plus resistance training).\n* Willing and able to undergo whole-body MRI at baseline and 6 months without sedation.\n* Able to understand procedures and provide written informed consent in English (at this time, MyNetDiary, a food-logging app used for tracking protein-intake, is only set up for English, and our RDN is only capable of providing nutritional counseling in English)\n\nExclusion Criteria:\n\n* Patients currently prescribed oral or injectable incretin mimetics containing GLP-1RAs, including Exenatide, Liraglutide, Lixisenatide, Dulaglutide, Semaglutide. Participants who are currently prescribed tirzepatide and have been using for \\>4 weeks will also be excluded.\n* Prior use of incretin mimetics containing GLP-1RAs with \\>3% weight loss in a 4-week period\n* Lost \\>5% body weight in the past 6 months\n* Has consistently resistance trained (\\>10 sessions) in the last year\n* Currently taking medication or supplements that have been shown to impact muscle function and muscle mass in the last 6 months\n* Participants who live outside of the tri-state area and\u002For are not willing to come to New York City for in-person visits outlined\n* Plans to be out of town more than 2 consecutive weeks or \\>6 weeks total over the next 6 months\n* Type 1 or 2 diabetes; uncontrolled diabetes (e.g., HbA1c \\> 6.4% if specified); recurrent severe hypoglycemia or hypoglycemia unawareness.\n* Moderate-to-severe chronic kidney disease (e.g., eGFR \\\u003C 45-60 mL\u002Fmin\u002F1.73 m2 final cutoff per protocol) or other renal disease\n* Decompensated cirrhosis, severe chronic liver disease, or active liver disease\n* Unstable cardiovascular disease (e.g., myocardial infarction (MI), stroke, coronary revascularization, or hospitalization for unstable angina or decompensated heart failure (HF) within \\\u003C6 months)\n* Active malignancy requiring systemic therapy in the past 6-months (excluding non-melanoma skin cancer)\n* Serious medical\u002Fpsychiatric conditions making participation unsafe or likely to impair adherence\n* Pregnant, planning pregnancy within 6 months, or breastfeeding; women of childbearing potential unwilling to use effective contraception per institutional\u002Fdrug-label guidance.\n* Conditions requiring protein restriction (e.g., advanced Chronic Kidney Disease (CKD), relevant inborn errors of metabolism).\n* Severe, poorly controlled gout\u002Fhyperuricemia\n* Significant GI disease impairing tolerance or absorption (e.g., active Inflammatory Bowel Disease (IBD) with frequent flares, short bowel syndrome, severe gastroparesis beyond expected GLP-1 effects)\n* Severe food allergies or intolerances that preclude a high-protein diet or ingestion of whey or pea protein and associated additives\u002Fingredients of the protein powders used in this study.\n* Has or previously had an eating disorder\n* Severe musculoskeletal, neuromuscular, or other conditions that preclude moderate-intensity RT\n* Advised not to exercise by their general practitioner or medical professional or refusal to obtain medical clearance if indicated by Physical Activity Readiness Questionnaire (PAR-Q) answers\n* Standard contraindications to MRI: tattoos with metallic ink, pacemaker, cerebral and\u002For cochlear implant, metal in the eye, severe claustrophobia, presence of electronic devices or ferromagnetic metallic foreign or implanted objects that could constitute a hazard, inability to lie flat, or any other contraindication for MRI.\n* Weight \\>200kg, or large body habitus which the MRI scanner cannot accommodate.\n* Inability or unwillingness to attend a reasonable proportion of RT sessions and refusal of accommodations\n* Concurrent enrollment in another weight management intervention\n* Prior bariatric surgery within the past 12 months or planned bariatric surgery within the 6-month study period.\n* Active alcohol or drug use disorder\n* Significant cognitive impairment or language barrier precluding informed consent or adherence\n* Any reason that could compromise the participants' safety, based on the judgment of the investigators and\u002For clinical coordinators.","30 Years","60 Years",{"count":52,"type":23},32,[26],"The primary objective of this study is to examine the effects of a high-protein diet (HP) paired with resistance training (RT) compared with a HP diet alone, on skeletal muscle mass (SMM) volume of the (a) quadriceps and (b) rhomboids, and upper and lower body muscle strength in adults recently prescribed tirzepatide. The secondary objectives of this study are to compare changes in resting energy expenditure (REE), adaptive thermogenesis (AT), and body adiposity (SFV, VAT, and intramuscular FF) in the quadriceps and rhomboid muscles) between the high-protein diet with RT and the high-protein diet arms at 6 months.",[56],"Weight Loss",[58,59],"GLP-1","tirzepatide","NOT_YET_RECRUITING","2026-07-07",{"date":33,"type":34},{"date":64,"type":23},"2026-07",{"date":66,"type":23},"2027-12",{"name":40,"class":41},{"id":69,"slug":70,"hasResults":12,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":12,"sex":18,"minAge":74,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":24,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":86,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":42},"100053508","noise-reduction-with-hearing-aids-100053508","NCT07700043","Noise Reduction With Hearing Aids","Inclusion Criteria:\n\n* 16 years of age and older\n* Bilateral sensorineural hearing loss. Hearing loss will be diagnosed as sensorineural by an air-bone gap of no more than 10 dB averaged across 0.5, 1, 2, and 3 kHz and Type A tympanograms.\n* Mild, moderate, or severe hearing loss. Hearing loss classification will be dependent on 4-frequency pure tone average (PTA, 0.5, 1, 2 and 4kHz) in the test ear. The mild group will have a PTA of 25-40 dB HL; moderate group will have a PTA of 41-60 dB HL; the severe group will have a PTA of 61-90 dB HL.\n* Be willing and able to provide consent.\n\nExclusion Criteria:\n\n* under 16 years of age\n* Participants with conductive or mixed hearing loss (i.e. have more than a 10 dB air-bone gap averaged across 0.5, 1, 2, and 3 kHz or tympanograms other than Type A)","16 Years",{"count":76,"type":23},60,[26],"The purpose of this study is to use an optimized version of the SEDA algorithm (SEDA-HA) for hearing aids to evaluate the benefit for listeners with varying degrees of hearing loss in realistic environments and evaluate its impact on speech perception and sound quality. The primary objective is to evaluate performance with and without the SEDA-HA algorithm on speech perception and speech reception tasks. The secondary objective is to evaluate performance of and experience with SEDA-HA integrated into a portable hearing aid prototype in the laboratory and in real-world situations outside the laboratory.",[80],"Bilateral Sensorineural Hearing Loss",[82,83,84,85],"Hearing aid","Hearing loss","Cochlear Implant","CI",{"date":33,"type":34},{"date":88,"type":23},"2026-09",{"date":90,"type":23},"2029-09",{"name":40,"class":41},{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":99,"targetDuration":4,"studyType":24,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100641059","implementation-of-communication-disability-collection-and-accommodations-in-primary-care-settings-100641059","NCT07656584","Implementation of Communication Disability Collection and Accommodations in Primary Care Settings","DECA","Inclusion Criteria:\n\nEHR Data Extraction\n\n1. Adults 18+ years\n2. Patients who had at least one visit within the 21-month EHR data collection period at participating study clinics.\n\nClinic Leadership, Providers \\& Clinic Staff\n\n1. Adults 18+ years\n2. Individuals of all genders and members of all racial and ethnic categories employed at participating study clinics will be eligible for inclusion. NYULH study personnel will enroll providers and staff referred for study inclusion from all participating study clinics; not just NYULH staff exclusively.\n\nPatients\n\n1. Adults 18+ years\n2. Patients with communication disabilities seen at least once at participating study clinics during the 21-month study period.\n3. Patients who self-identify as proficient in English communication as defined by English being a preferred language, or self-reported ability to participate in an interview in English without the support of an interpreter.\n\nExclusion Criteria:\n\nEHR Data Extraction\n\n1. Patients whose records are unavailable due to technical issues.\n2. Patients who are not seen at least once at participating study clinics during the 21-month data collection period.\n3. Duplicate records (e.g., duplicative EHR records marked for deletion).\n4. Patients who have opted-out of research participation.\n\nClinic Leadership, Providers \\& Clinic Staff Interviews and Focus Groups\n\n1. Being \\\u003C18 years old\n2. Not an employed member of a participating study clinic or potential end user of the study implementation strategy.\n\nPatient Interviews\n\n1. Being \\\u003C18 years old\n2. Patients without communication disabilities.\n3. Patients with communication disabilities seen outside of participating study clinics.\n4. Patients who are unable to provide consent for themselves.\n5. Patients who report not being proficient in English communication or self-reported inability to participate in an interview in English without the support of an interpreter.",{"count":100,"type":23},126870,[26],"This multi-methods-multi-site study aims to adapt and evaluate the effects of an implementation support package of strategies to assist primary care clinics in documenting patients' communication disability (CD) and accommodation needs in the electronic health record (EHR) and providing communication accommodations through EHR data extraction, surveys, focus groups, interviews, and clinical practice observations.",[104],"Communication Disabilities","2026-07-01",{"date":107,"type":34},"2026-07-02",{"date":36,"type":34},{"date":110,"type":23},"2027-05-31",{"name":40,"class":41},5,{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":120,"minAge":19,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":24,"phases":123,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":42},"100641168","sexual-health-communication-skills-training-intervention-for-patients-with-prostate-cancer-100641168","NCT07655557","Sexual Health Communication Skills Training Intervention for Patients With Prostate Cancer","Pilot Testing a Sexual Health Communication Skills Training Intervention for Patients With Prostate Cancer","Inclusion Criteria:\n\n* Adult male with PCa at least 18 years of age\n* Speak English\n* Reside in the U.S.\n* Have internet\u002Fweb access, and\n* Report current bother due to sexual dysfunction\n* Capacity and willingness to provide consent\n* Have an appointment with a PCa provider at NYU Langone Health during the study accrual period\n\nExclusion Criteria:\n\n* Individual with impaired decision-making capacity.\n* Participation in another part of this study (prior aim)","MALE",{"count":122,"type":23},100,[26],"This is a pilot randomized controlled trial of a sexual health communication skills training multimedia intervention (Starting the Conversation \\[STC\\] adapted for patients with prostate cancer \\[PCa\\]) to improve patients' ability to communicate with providers about their sexual health concerns during PCa care compared to a time and attention control arm.",[126],"Prostate Cancer",[126,128,129],"Sexual Health","Health Communication","2026-06-29",{"date":105,"type":34},{"date":133,"type":23},"2026-08-01",{"date":135,"type":23},"2028-10-31",{"name":40,"class":41},{"id":138,"slug":139,"hasResults":12,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":42},"100601765","early-cochlear-implant-use-100601765","NCT07114744","Early Cochlear Implant Use","Inclusion Criteria:\n\n1. Postlingually deaf cochlear implant users\n2. severe or profound hearing loss\n3. who do not have other diagnoses communicative or cognitive disorders.\n4. Test population: no prior experience with cochlear implants (recruitment happens prior to cochlear implantation).\n5. Control population: subjects who have used the same stimulation strategy since initial stimulation, who note no continuing improvements or changes with their devices with respect to speech comprehension.\n\nExclusion Criteria:\n\n1. Diagnosed cognitive or communicative disorders (other than deafness)\n2. Below 18 years of age\n3. Above the age of 85 years old.","85 Years",{"count":7,"type":23},"OBSERVATIONAL","This observational study will examine newly activated cochlear implant users and determine whether their abilities to discern simple sounds change and relate to improved speech perception. Take-home computers and test-equipment will be sent home, and subjects will complete approximately 25 test sessions over the first 3 months of cochlea implant use. Then, subjects will be tested 3 more times in the laboratory until 1 year-post activation. The primary objective is to determine and quantify how sounds change and speech perception improves over the course of early cochlear implant use.",[148],"Cochlear Implant Users",{"date":105,"type":34},{"date":151,"type":34},"2025-06-11",{"date":153,"type":23},"2027-07-01",{"name":40,"class":41},{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":18,"minAge":162,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":24,"phases":166,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":42},"100601507","feasibility-of-home-based-intermittent-60hz-light-therapy-for-major-depressive-disorder-mdd-100601507","NCT07111390","Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)","A Feasibility Pilot Study of Home-Based Intermittent 60Hz Light Therapy for the Treatment of Depression","Inclusion Criteria:\n\n* Age between 24 and 65 years (inclusive)\\*.\n* Confirmed diagnosis of Major Depressive Disorder (MDD), based on MINI interview.\n* Hamilton Depression Rating Scale (HDRS-17) score ≥17 at screening.\n* On a stable dose of antidepressant medication for at least 30 days prior to HDRS-17 screening.\n* No evidence of premorbid cognitive impairment, as demonstrated by a standard score \\>85 on the WRAT-5 Reading Recognition Subtest.\n* Confirmed access to a local provider that has primary responsibility for the subjects' clinical care, and who is available for contact in case of increased subject risk due to depressive symptoms.\n* Able to provide informed consent and comply with study procedures.\n* Access to a quiet space suitable for home-based light stimulation sessions.\n* English speaking: All study materials and assessments are only validated in English\n\nExclusion Criteria:\n\n* Presence of primary neurological or autoimmune disorders.\n* Presence of psychiatric comorbidities as determined by the MINI interview (e.g., anxiety disorders, OCD, PTSD, bipolar disorder, psychotic disorder).\n* Current or recent diagnosis of alcohol or substance use disorder.\n* History of bipolar disorder or any psychotic disorder.\n* Clinically significant suicidal ideation or behavior, based on clinician judgment and the Columbia-Suicide Severity Rating Scale (C-SSRS).\n* History of seizure disorder or epilepsy.\n* History of migraine, tinnitus, or photosensitivity.\n* Diagnosis of retinal disease, cataract, or other visual impairments that may interfere with light exposure.\n* Regular use of anti-inflammatory drugs or anticoagulants (e.g., clopidogrel).\n* Pregnancy and Breastfeeding: Currently pregnant, planning pregnancy during the study period, or breastfeeding","24 Years","65 Years",{"count":165,"type":23},40,[26],"This pilot study evaluates the feasibility, safety, and preliminary efficacy of home-based 60Hz intermittent light therapy in adults with a major depressive episode (MDE). Participants will be randomized in a 2:1 ratio to receive either active or sham 60Hz intermittent light stimulation for 30 minutes daily (Monday through Friday) over three weeks. The light is delivered through a wearable headset. Clinical assessments will be conducted remotely at baseline, mid-point, post-treatment, and follow-up to measure changes in depressive symptoms.",[169,170,171,172],"Depression","MDD","Major Depressive Disorder","Major Depressive Episode",[174,170,169,175,176,177,178],"Brain stimulation","Light therapy","Wearable","Neuromodulation","Telehealth","2026-06-25",{"date":130,"type":34},{"date":182,"type":34},"2025-08-18",{"date":184,"type":23},"2027-02-01",{"name":40,"class":41},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":163,"enrollmentInfo":193,"targetDuration":4,"studyType":24,"phases":195,"briefSummary":197,"conditions":198,"keywords":200,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":42},"100585386","phase-2-home-based-transcranial-direct-current-stimulation-tdcs-for-depression-in-multiple-sclerosis-ms-100585386","NCT06901687","Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)","Home-Based tDCS for Depression in Multiple Sclerosis: A Randomized Sham-Controlled Trial","Inclusion Criteria:\n\n* Age: 18-65 years (inclusive)\n* Diagnosis: Confirmed diagnosis of multiple sclerosis (MS), including relapsing-remitting or secondary progressive subtypes\n* Stable Medications: Stable use of antidepressant and disease-modifying therapies (DMTs) for at least 30 days prior to enrollment\n* Stable Disease Activity: Defined as no clinical relapse, no new radiological disease activity, and no recent steroid treatment for at least 30 days prior to enrollment\n* Provider Contact: Confirmed access to a local provider that has primary responsibility for the subjects' clinical care, and who is available for contact in case of increased subject risk due to depressive symptoms\n* Technical Ability: Ability to use mobile devices and participate in remote, video-supervised sessions\n\nExclusion Criteria:\n\n* Neurological or Medical Disorders: History of primary neurological disorder other than MS (e.g., stroke, Parkinson's disease, traumatic brain injury (TBI), intracranial mass, epilepsy, mild cognitive impairment (MCI), dementia), major psychiatric disorders (e.g., bipolar disorder, psychotic disorders), or serious medical conditions (e.g., myocardial infarction, thyroid disease, diabetes with complications, atrial fibrillation)\n* Substance Use: Nicotine use (e.g., smoking or vaping) within the past 6 months\n* Pregnancy and Breastfeeding: Currently pregnant, planning pregnancy during the study period, or breastfeeding. If able to become pregnant, participants will be required to use medically accepted birth control methods, including hormonal methods (e.g., pills, patches, implants), barrier methods (e.g., condoms or diaphragm with spermicide), intrauterine device (IUD), or abstinence. Participants will be advised not to become pregnant during the study.\n* Seizure History: History of seizures or seizure disorder within the past 5 years\n* Implanted Devices or Metal Objects: Presence of metal in the head\u002Fneck area (excluding dental fillings) or implanted medical devices (e.g., neurostimulators, pacemakers, defibrillators)\n* Skin Conditions: Active skin disorders or skin sensitivity near electrode application sites",{"count":194,"type":23},170,[196],"PHASE2","This project is a double-blind, sham-controlled, parallel-arm, randomized controlled trial. We will recruit n=170 people living with MS, who are experiencing an episode of depression in the context of a major depressive episode (MDE). Using our remotely supervised (RS) tDCS protocol, enrolled participants will complete 30 days of 30-minute tDCS (2.0, DLPFC left anodal) while listening to mindfulness meditation. Over the course of the study, participants will complete assessments of depression and MS symptoms. Participants will be randomized 1:1 active:sham tDCS.",[199,169],"Multiple Sclerosis",[199,169,177,201,202],"Home-Based","transcranial direct current stimulation",{"date":130,"type":34},{"date":205,"type":34},"2025-08-11",{"date":207,"type":23},"2028-06-01",{"name":40,"class":41},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":24,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":229,"locationsCount":42},"100565104","optimal-dosing-of-high-intensity-locomotor-training-for-step-attainment-and-locomotor-outcomes-in-stroke-patients-undergoing-acute-inpatient-rehabilitation-100565104","NCT06637839","Optimal Dosing of High-Intensity Locomotor Training for Step Attainment and Locomotor Outcomes in Stroke Patients Undergoing Acute Inpatient Rehabilitation","A Randomized, Double-blind Study Comparing the Effects of Three Distinct High Intensity Locomotor Training Protocols on Locomotor Outcomes in Subacute Stroke Patients Undergoing Adult Inpatient Rehabilitation.","Inclusion Criteria:\n\n• Primary diagnosis of stroke\n\nExclusion Criteria:\n\n* Weightbearing restrictions, uncontrolled cardiopulmonary, metabolic, infectious, or psychiatric disorders, which would preclude aerobic locomotor training\n* Estimated length of stay of less than 14 days\n* Non-ambulatory status prior to admission (unable to walk \\>50 meters)\n* Pregnant","95 Years",{"count":218,"type":23},20,[26],"The purpose of this study is to elucidate optimal dosing for High Intensity Gait Training (HIGT) to reduce locomotor disability for those undergoing inpatient rehabilitation (IR) in the subacute phase of stroke recovery.\n\nThis is a randomized controlled trial conducted at a single IR facility. Investigators will randomize patients to receive one of two distinct HIGT interventions or a high step count intervention during standard care.",[222],"Stroke","2026-06-24",{"date":225,"type":34},"2026-06-26",{"date":227,"type":23},"2027-01",{"date":66,"type":23},{"name":40,"class":41},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":239,"briefSummary":241,"conditions":242,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":247,"leadSponsor":249,"locationsCount":4},"100644687","phase-1-phase-1-study-of-wbrt-or-pcsi-with-reyobiq-for-leptomeningeal-metastases-100644687","NCT07674693","Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases","A Phase 1 Study to Determine the Safety and Tolerability of Whole Brain Radiotherapy (WBRT) or Proton Craniospinal Irradiation (PCSI) With Multiple Doses of Rhenium-186 NanoLiposome (186RNL, REYOBIQ) Administered Via Intraventricular Catheter for Leptomeningeal Metastases","Inclusion Criteria:\n\n* At least 18 years of age at screening\n* Ability to understand the purposes and risks of the study and has signed a written informed consent document approved by the site-specific IRB\n* Proven and documented LM evidenced by positive CSF cytology or CSF circulating tumor cells, from any primary solid tumor\n* Patients may have received prior chemotherapy regimens and prior radiation (there is no limit)\n* Karnofsky performance status of 60 to 100\n* Acceptable liver function:\n\n  * Bilirubin ≤ 1.5 times upper limit of normal\n  * AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal for subjects with normal liver\n  * AST (SGOT) and ALT (SGPT) ≤ 5.0 times upper limit of normal for subjects with liver metastasis\n* Subjects with a creatinine clearance greater than or equal to 60 mL\u002Fmin (using the Cockcroft-Gault Equation) for males and females.\n* Acceptable hematologic status (without hematologic support):\n\n  * ANC ≥ 1000 cells μL\n  * Platelet count ≥ 75,000\u002FμL\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * PT\u002FINR and PTT ≤1.5 x ULN, unless treated with anticoagulants\n* All women of childbearing potential must have a negative serum pregnancy test at screening. Male and female subjects must agree to use effective means of contraception (for example, surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose.\n\nExclusion Criteria:\n\n* The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v6.0) Grade ≤ 1 from AEs due to antineoplastic agents, investigational drugs, or other medications that were administered prior to study. Prior AEs due to alopecia, anemia, and lymphopenia are not required to be recovered to Grade ≤ 1 prior to 186RNL treatment, assuming other inclusion criteria are satisfied.\n* Ventriculo-peritoneal or ventriculo-atrial shunts or contraindications to placement of Ommaya reservoir.\n* Females of childbearing potential who are pregnant, breast feeding, or may possibly be pregnant without a negative serum pregnancy test (see inclusion criteria).\n* Serious intercurrent illness, clinically significant cardiac arrhythmias, uncontrolled systemic infection, symptomatic congestive heart failure or unstable angina pectoris within 3 months prior study drug, myocardial infarction, stroke, transient ischemic attack within 6 months, seizure disorder with any seizure occurring within 14 days prior to consenting or encephalopathy.\n* Active severe non hematologic organ dysfunction such as renal, cardiac, hepatic, pulmonary, or gastrointestinal grade 3 or above.\n* Toxicity from prior treatments (grade 3 or above) that have not subsided to grade 1.\n* Patients with prior CNS directed EBRT.\n* Cytotoxic systemic therapy is excluded if given within 14 days or 5 half-lives, whichever is shorter, prior to 186RNL treatment. Small-molecule kinase inhibitors, targeted therapies, immunotherapy, and hormonal therapy can be given up to the day of treatment per investigator discretion.\n* Projected survival of less than 60 days.",{"count":238,"type":23},29,[240],"PHASE1","This Phase 1 study is designed to assess the safety, tolerability, and schedule feasibility of administering Rhenium-186 NanoLiposome (REYOBIQ) at different dosing intervals following whole brain radiotherapy (WBRT) or proton craniospinal irradiation (PCSI).",[243],"Leptomeningeal Metastases","2026-06-23",{"date":130,"type":34},{"date":64,"type":23},{"date":248,"type":23},"2031-07",{"name":40,"class":41},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":271},"100601909","catch-a-vibe---24-00864-100601909","NCT07116629","Catch A Vibe - 24-00864","A Community-Based Intervention To Address Health-Related Social Needs For Patients On LAI-PrEP","Inclusion Criteria:\n\nFor Patient participant group: In order to be eligible for participation in this study, an individual must meet all of the following criteria:\n\n* 18 years of age or older\n* Does not have HIV AND vulnerable for HIV infection per WHO, NHS, and CDC recommendations\n* On or initiating LAI-PrEP as part of standard of care prior to study participation\n* Identify as either a Black\u002FLatine cisgender woman OR Black\u002FLatine MSM OR Transgender or Nonbinary Individual\n* Capacity and willingness to provide consent\n\nFor Medical Staff participant group: In order to be eligible for participation in this study, an individual must meet all of the following criteria:\n\n* 18 years of age or older\n* Works with patients who go to the Bellevue Pride Center\n* Be employed at NYU Langone Health or NYC H+H\u002FBellevue as one of the following occupations\n\n  * Physician\n  * Clinical Pharmacist\n  * Nurse\n  * Medical Phlebotomist\n  * Social Worker\u002FNavigator\n  * Community Health Worker\n  * Medical Leader (i.e., director of services)\n\nFor CBO Partner participant group: In order to be eligible for participation in this study, an individual must meet all of the following criteria:\n\n* 18 years of age or older\n* Works with patients who go to the Bellevue Pride Center\n* Be employed at one of the established CBOs\n* Capacity and willingness to provide consent\n\nFor Patient Who Declines LAI-PrEP participant group: In order to be eligible for participation in this study, an individual must meet all of the following criteria:\n\n* 18 years of age or older\n* Declines LAI-PrEP as part of standard of care\n* Capacity and willingness to provide consent\n\nExclusion Criteria:\n\nFor Patient participant group: An individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Less than 18 years old\n* Known HIV seropositive status or test positive at screening\n* Does not identify as one of the listed priority populations\n* Not fluent in either English or Spanish\n* Not interested in HIV PrEP\n* Not willing to consent for study participation\n* Does not reside within New York State\n* Pregnant or planning to become pregnant at the time of consent.\n* Without capacity to consent to participate in the study\n\nFor Medical Staff participant group: An individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Do not work with patients who go to the Bellevue Pride Center\n* Is not employed at NYU Langone Health or NYC\u002FH+H Bellevue as one of the following occupations\n\n  * Physician\n  * Clinical Pharmacist\n  * Nurse\n  * Medical Phlebotomist\n  * Social Worker\n  * Community Health Worker\n  * Medical Leader (i.e., directors of services)\n\nFor CBO Partner participant group: An individual who meets any of the following criteria will be excluded from participation in this study:\n\n• Does not work with patients who go to the Bellevue Pride Center\n\nFor Patient Who Declines LAI-PrEP participant group: An individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Less than 18 years old\n* Interested in initiating LAI-PrEP as part of standard of care or on LAI-PrEP",{"count":258,"type":23},343,"This study evaluates a proposed community-based implementation strategy to scale up screening, identification, and intervention on Health-Related Social Needs (HRSN) among persons on Long-Acting Injectable Pre-exposure Prophylaxis (LAI-PrEP). To do so, (1) screening for HRSN will occur at provider visits every 4 months, (2) navigation and establishment of connections with community resources through collaboration with two established community-based organization (CBO) partners, and (3) development of a tracking system integrated into the Electronic Medical Record (EMR) for monitoring and assessment of referral outcomes.",[261],"Health-Related Social Needs",[263,264,261],"LAI-PrEP","Community Partnerships",{"date":225,"type":34},{"date":267,"type":34},"2025-10-22",{"date":269,"type":23},"2028-05",{"name":40,"class":41},2,{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":24,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":42},"100567110","clinical-evaluation-of-frequency-allocation-for-bimodal-ci-users-100567110","NCT06663917","Clinical Evaluation of Frequency Allocation for Bimodal CI Users","Inclusion Criteria:\n\n1. Age 18 or older\n2. Regular usage of a cochlear implant device with at least 18 active electrodes, and compliance with programming\u002Fappointments\n3. Received a cochlear implant at least 6 months ago and use a hearing aid in the contralateral ear\n4. Pure tone average (.5, 1, and 2kHz) between 30 and 70 dB (decibel) hearing level in the contralateral (hearing aid) ear\n5. Standard FAT use for all programs prior to study participation\n6. No known anatomical abnormalities in either ear\n7. English speaking\n8. No known cognitive impairments\n9. At least 25% of subjects should use the Cochlear EA32 electrode\n\nExclusion Criteria:\n\n1. Under age 18\n2. Non-English speaking. Participants that are Non-English speaking are excluded from this study due to the use of speech testing materials that are validated in the English language. Additionally, study team members are not equipped to appropriately score speech testing materials validated in other languages.\n3. Cognitively impaired\n4. Non-consistent device usage\n5. Greater than 70 dB hearing level pure tone average in the contralateral ear\n6. Normal hearing or mild hearing loss in the contralateral ear\n7. Non-standard FAT programs\n8. Use of any frequency transposition programming in hearing aid.",{"count":279,"type":23},13,[26],"This study will examine experienced, bimodal cochlear implant (CI) patients who receive an alternative frequency allocation table (FAT) to determine how it improves sound quality, device satisfaction, and speech perception abilities with respect to the standard default FAT. The goal of this study is to investigate how improving place-pitch mismatch in bimodal CI users affects 1) sound quality, 2) satisfaction, and 3) speech perception.",[283],"Hearing Impairment",{"date":225,"type":34},{"date":286,"type":34},"2024-10-06",{"date":288,"type":23},"2027-10-06",{"name":40,"class":41},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":143,"enrollmentInfo":297,"targetDuration":4,"studyType":24,"phases":299,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":271},"100441796","phase-3-smartphones-for-opiate-addiction-recovery-100441796","NCT05033028","Smartphones for Opiate Addiction Recovery","SOAR","Inclusion Criteria:\n\nPatients:\n\n* Meet DSM-5 criteria for opioid-use disorder (heroin and\u002For prescription opioids);\n* Have entered, or expressed a clear intention to enter, an OUD treatment program that prescribes either methadone or buprenorphine\n* Any gender;\n* 18 years of age and older;\n* Have used opioids other than as specifically prescribed within thirty days prior to consent;\n* In good-enough general health;\n* Capacity to provide written informed consent as assessed by our Subject Comprehension Assessment Tool(subjects lacking the ability to consent will not be enrolled) ;\n* Able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study.\n\nStudy-Physician Participants.\n\n* Licensed MD employed by the respective site, or at a clinical partner of the respective site, where they will act as participants and be part of the treatment team\n* Currently practicing in the treatment of OUD with either Buprenorphine or Methadone;\n* Able to speak, read, and write English fluently and to provide informed consent in English\n\nClinician Participants.\n\n* Licensed MSW, NP, or MD; who are not part of any treatment team within the study and may be employees of their respective sites or other treatment facilities.\n* Currently practicing in the treatment of OUD with either Buprenorphine or Methadone;\n* Able to speak, read, and write English fluently and to provide informed consent in English\n\nExclusion Criteria:\n\nPatients:\n\n* Serious medical, psychiatric or non-opioid substance use disorder that, in the opinion of a study physician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include: (a) Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and\u002For laboratory assessments;\n* Severe, untreated or inadequately treated mental disorder (e.g., active psychosis, uncontrolled manic-depressive illness) as assessed by history and\u002For clinical interview;\n* Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use likely to require a complicated medical detoxification (routine alcohol and sedative detoxifications may be included);\n* Suicidal or homicidal ideation that requires immediate attention;\n* Presence of pain of sufficient severity as to require ongoing pain management with opioids;\n* Pending legal action or other reasons that might prevent an individual from completing the study.\n* Pregnancy as assessed by urine pregnancy testing\n* Breastfeeding of infants, as assessed by self-report.\n* Prisoners, as defined by OHRP, are excluded from participation in the study.\n* Individuals receiving residential court-ordered substance abuse treatment.\n\nStudy-Physician Participants.\n\n* none\n\nClinician Participants.\n\n* none",{"count":298,"type":23},225,[300],"PHASE3","Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates the numerical probability that a patient will reuse illicit opiates within the next 7-10 days.",[303],"Opioid-use Disorder","2026-06-22",{"date":244,"type":34},{"date":307,"type":34},"2021-11-01",{"date":309,"type":23},"2027-12-01",{"name":40,"class":41},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":42},"100641967","evaluating-the-effectiveness-of-a-colonoscopy-surveillance-recommendations-algorithm-in-clinical-practice-100641967","NCT07658716","Evaluating the Effectiveness of a Colonoscopy Surveillance Recommendations Algorithm in Clinical Practice","Inclusion Criteria:\n\n* Gastroenterologists and primary care physicians, including residents and fellows, currently practicing at NYU Langone Health, and Bellevue.\n* Willing and able to provide consent\n\nExclusion Criteria:\n\n* Physicians not practicing in relevant fields or those with conflicts of interest.",{"count":122,"type":23},"The primary objective is to determine if the use of the colonoscopy surveillance recommendations algorithm increases the accuracy of surveillance timing recommendations compared to traditional methods. The secondary objective is to assess the time required to make surveillance recommendations with and without the algorithm, determine the efficiency gains (the average time saved per recommendation), and evaluate the opportunity cost (the financial value of the time saved).",[320],"Colonoscopy","2026-06-16",{"date":304,"type":34},{"date":324,"type":34},"2026-03-24",{"date":326,"type":23},"2028-03-24",{"name":40,"class":41},{"id":329,"slug":330,"hasResults":12,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":24,"phases":336,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":345,"leadSponsor":347,"locationsCount":42},"100642666","phase-4-postoperative-non-opioid-pain-management-utilizing-local-anesthetics-coupled-with-modulated-coagulation-100642666","NCT07644923","Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation","A Randomized, Single-Blinded, Controlled Study Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation","Inclusion Criteria:\n\n* Age 18 or older\n* Any patient undergoing elective hand surgery\n\nExclusion Criteria:\n\n* Any patient with a traumatic or infected open wound (only surgically created wounds will be included)\n* History of chronic pain\n* History of narcotic addiction\n* History of recreational drug dependency\n* History of psychiatric pathology\n* Allergy or hypersensitivity to local anesthetics, recombinant human thrombin or tranexamic acid\n* History of coagulopathy or active thromboembolic disease\n* Any patient receiving a supra\u002Finfraclavicular block for anesthesia\n* Pregnancy\n* Hypersensitivity to hamster proteins\n* History of seizures\n* Significant renal impairment (chronic kidney disease stage 3 or greater)\n* History of retinal vascular disease or history of unexplained visual symptoms\n* Active upper urinary tract bleeding\n* History of known hypercoagulable disorder, prior thromboembolic events, or active clotting disorders\n* History of severe hepatic dysfunction (active hepatitis or steatohepatitis, hepatic fibrosis considered cirrhosis)",{"count":165,"type":23},[337],"PHASE4","This study is a prospective randomized trial examining the effect of tranexamic acid (TXA) and aminocaproic acid (ε-Ahx) with local anesthetics and thrombin in all electively created surgical wound beds in hand surgery to provide long term pain relief and decrease the use of postoperative narcotics.\n\nAll surgical created wounds for any hand surgery will be treated in a randomized fashion with the following four arms:\n\n1. Bupivacaine + lidocaine\n2. Bupivacaine + lidocaine + thrombin\n3. Bupivacaine + lidocaine + thrombin + tranexamic acid\n4. Bupivacaine + lidocaine + thrombin + aminocaproic acid\n\nAll are applied topically to surgical bed prior to closure of skin.",[340],"Postoperative Pain","2026-06-09",{"date":343,"type":34},"2026-06-12",{"date":133,"type":23},{"date":346,"type":23},"2029-02-01",{"name":40,"class":41},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":373},"100193894","natural-history-study-of-synucleinopathies-100193894","NCT01799915","Natural History Study of Synucleinopathies","Inclusion Criteria:\n\n1. Both male and female patients will be included\n2. Aged 18 or over\n3. Referred to any of the participating consortium sites with orthostatic intolerance, defined as symptoms of dizziness or lightheadedness in the standing position that disappear when supine.\n\nExclusion Criteria:\n\n1. Diabetes according to the American Diabetes Association criteria\n2. Congestive heart failure\n3. Lupus or other collagen vascular disease\n4. Systemic illness thought to be responsible for the orthostatic intolerance\n5. Drug-induced orthostatic hypotension (i.e., the use of alpha-blockers, diuretics, tricyclic antidepressants or others thought by the investigator to play an important role in the patient's orthostatic hypotension)\n6. Isolated vasovagal syncope\n7. Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.",{"count":355,"type":23},800,"Synucleinopathies are a group of rare diseases associated with worsening neurological deficits and the abnormal accumulation of the protein α-synuclein in the nervous system. Onset is usually in late adulthood at age 50 or older. Usually, synucleinopathies present clinically with slowness of movement, coordination difficulties or mild cognitive impairment. Development of these features indicates that abnormal alpha-synuclein deposits have destroyed key areas of the brain involved in the control of movement or cognition. Patients with synucleinopathies and signs of CNS-deficits are frequently diagnosed with Parkinson disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA).\n\nHowever, accumulation of alpha-synuclein and death of nerve cells can also begin outside the brain in the autonomic nerves. In such cases, syncucleinopathies present first with symptoms of autonomic impairment (unexplained constipation, urinary difficulties, and sexual dysfunction). In rare cases, hypotension on standing (a disorder known as orthostatic hypotension) may be the only clinical finding. This \"pre-motor\" autonomic stage suggests that the disease process may not yet have spread to the brain.\n\nAfter a variable period of time, but usually within 5-years, most patients with abnormally low blood pressure on standing develop cognitive or motor abnormalities. This stepwise evolution indicates that the disease spreads from the body to the brain. Another indication of this spread is that acting out dreams (i.e., REM sleep behavior disorder, RBD) a problem that occurs when the lower part of the brain is affected, may also be the first noticeable sign of Parkinson disease.\n\nThe purpose of this study is to document the clinical features and biological markers of patients with synucleinopathies and better understand how these disorders evolve over time. The study will involve following patients diagnosed with a synucleinopathy (PD\u002FDLB and MSA) and those believed to be in the \"pre-motor\" stage (with isolated autonomic impairment and\u002For RBD). Through a careful series of follow-up visits to participating Centers, we will focus on finding biological clues that predict which patients will develop motor\u002Fcognitive problems and which ones have the resilience to keep the disease at bay preventing spread to the brain. We will also define the natural history of MSA - the most aggressive of the synucleinopathies.",[358,359,360,361,362,363,364,365],"Patients With Synucleinopathies","Neurogenic Orthostatic Hypotension","Pure Autonomic Failure","REM Sleep Behavior Disorder","Parkinson Disease","Dementia With Lewy Bodies","Multiple System Atrophy","Shy-Drager Disease",{"date":367,"type":34},"2026-06-10",{"date":369,"type":34},"2011-06",{"date":371,"type":23},"2026-12-30",{"name":40,"class":41},8,{"id":375,"slug":376,"hasResults":12,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":17,"sex":18,"minAge":381,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":24,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":42},"100590609","influence-of-likes-in-social-media-food-ads-on-black-and-white-adolescents-food-purchases---study-2-100590609","NCT06969638","Influence of \"Likes\" in Social Media Food Ads on Black and White Adolescents' Food Purchases - Study 2","A Randomized Trial to Examine the Influence of \"Likes\" in Social Media Food Ads on Black and White Adolescents' Food Purchases - Study 2","Inclusion Criteria:\n\n* adolescent (13-17 years of age) who identifies as only non-Latino White or only Black\u002FAfrican American; who logs into Instagram once daily; who can read and speak English\n\nExclusion Criteria:\n\n\\- participants who do not meet all criteria described above.","13 Years","17 Years",{"count":384,"type":23},1300,[26],"This is a randomized trial to examine the influence of number of \"likes\"on social media food ads on Black and White adolescents' food purchases",[388],"Food Selection","2026-06-08",{"date":367,"type":34},{"date":392,"type":34},"2025-04-29",{"date":394,"type":23},"2027-06",{"name":40,"class":41},{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":17,"sex":18,"minAge":381,"maxAge":382,"enrollmentInfo":403,"targetDuration":4,"studyType":24,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":413,"locationsCount":42},"100590610","effects-of-racial-congruence-likes-and-food-images-in-social-media-ads-on-adolescents-caloric-intake---study-3-100590610","NCT06969651","Effects of Racial Congruence, \"Likes\", and Food Images in Social Media Ads on Adolescents' Caloric Intake - Study 3","Comparing the Effects of Racial Congruence, \"Likes,\" and Food Images in Social Media Ads on Adolescents' Caloric Intake - Study 3","Inclusion Criteria:\n\n* adolescent (13-17 years of age) who identifies as only non-Latino White or only Black\u002FAfrican American; who logs into Instagram once daily; who can read and speak English\n\nExclusion Criteria:\n\n* \\- participants who do not meet all criteria described above",{"count":404,"type":23},480,[26],"This is a randomized trial to to test the degree to which visual attention to unhealthy foods, racially congruent people, and\u002For \"likes\" in social media ads explains the relationship between ad exposure and calorie intake.",[408],"Calorie Consumption",{"date":367,"type":34},{"date":411,"type":34},"2025-04-30",{"date":394,"type":23},{"name":40,"class":41},{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":163,"enrollmentInfo":421,"targetDuration":4,"studyType":24,"phases":422,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":42},"100636964","tdcs-sleep-to-mood-in-depression-s2m-d-100636964","NCT07572526","tDCS: Sleep to Mood in Depression (S2M-D)","Sleep Consolidation as a Mechanistic Pathway Linking Home-Based tDCS to Antidepressant Response (S2M-D)","Inclusion Criteria:\n\n1. Ability to read and understand study materials in English, as demonstrated by a standard score \\>85 on the WRAT-5 Reading Recognition Subtest\n2. MADRS-S ≥18 during screening\n3. Confirmed diagnosis of MDD, based on clinician interview\n4. If taking antidepressant medication, the dose must be stable for at least 30 days prior to pre-screening.\n5. Confirmed access to a local provider that has primary responsibility for the subjects' clinical care, and who is available for contact in case of increased subject risk due to depressive symptoms OR confirmed acknowledgement and identification of local resources.\n6. Able to provide informed consent and comply with study procedures.\n7. Access to a quiet space suitable for home-based tDCS stimulation sessions.\n\nExclusion Criteria:\n\n1. Current major medical condition that, in the opinion of the study clinician, would interfere with study participation, safety, or interpretation of study outcomes.\n2. Current or past bipolar disorder, psychotic disorder, or current (past 6 months) alcohol or substance use disorder, as determined by clinician assessment at screening.\n3. Clinically significant suicidal ideation or behavior, based on clinician assessment and the Columbia-Suicide Severity Rating Scale (C-SSRS).\n4. Use of prescription or over-the-counter sleep-promoting medications or initiation of behavioral interventions specifically targeting sleep in the past 30 days from pre-screening.\n5. History of seizure disorder or epilepsy.\n6. Presence of an active implanted medical device above the neck (e.g., deep brain stimulator, cochlear implant) or non-MRI-compatible metallic implants in the head or neck region.\n7. Current use of prescription or over-the-counter sleep medications, or active participation in any behavioral or pharmacologic treatment specifically targeting sleep.\n8. Pregnancy and Breastfeeding: Currently pregnant, planning pregnancy during the study period, or breastfeeding o If able to become pregnant, participants will be required to use medically accepted birth control methods, including hormonal methods (e.g., pills, patches, implants), barrier methods (e.g., condoms or diaphragm with spermicide), intrauterine device (IUD), or abstinence. Participants will be advised not to become pregnant during the study.",{"count":22,"type":23},[26],"The purpose of this study is to determine whether changes in sleep consolidation occur during home-based transcranial direct current stimulation (tDCS) in adults with moderate depression and whether these changes are temporally associated with improvements in depressive symptoms.",[171,170,169,172],[170,174,169,426,177,176,178],"tDCS","2026-06-05",{"date":389,"type":34},{"date":430,"type":34},"2026-06-04",{"date":432,"type":23},"2027-12-31",{"name":40,"class":41},{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":24,"phases":442,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":446,"startDateStruct":447,"completionDateStruct":449,"leadSponsor":451,"locationsCount":42},"100598958","improving-food-access-in-east-flatbush-through-a-community-partner-coalition-in-new-york-city-nyc-100598958","NCT07078253","Improving Food Access in East Flatbush Through a Community Partner Coalition in New York City (NYC)","Inclusion Criteria:\n\n1. Adult at least 18 years old\n2. Able to complete the surveys in English or Haitian Creole\n3. Able to travel to Brooklyn Center for Quality Life in East Flatbush weekly to pick up the no-cost fresh vegetables\n4. Willing and able to provide informed consent to participate in the study\n\nExclusion Criteria:\n\n1\\) Those not meeting the above inclusion criteria",{"count":441,"type":23},250,[26],"The objective of this research study is to implement and evaluate a food pantry pilot program to improve access to food and overall diet quality in East Flatbush. This will be achieved through the implementation of a tailored, client-choice food pantry pilot program. The pilot program will specifically offer locally grown produce.",[445],"Food Insecurity",{"date":341,"type":34},{"date":448,"type":34},"2025-05-19",{"date":450,"type":23},"2027-03-31",{"name":40,"class":41},{"id":453,"slug":454,"hasResults":12,"nctId":455,"briefTitle":456,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":12,"sex":18,"minAge":459,"maxAge":460,"enrollmentInfo":461,"targetDuration":4,"studyType":24,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":42},"100440801","phase-2-cannabidiol-cbd-in-pain-reduction-for-knee-osteoarthritis-100440801","NCT05020028","Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis","The Use of Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis. A Double-Blind, Randomized Control Study","Inclusion Criteria:\n\n* Patients presenting with knee osteoarthritis (KL Grade II-III)\n* Knee pain for at least three months, occurring in at least half of the days in that period\n* VAS ≥ 4\n* Patients ages 40-75, inclusive\n* If female patients are pre-menopausal they must be currently practicing effective forms of two types of birth control, which are defined as those, alone or in combination, that result in a low failure rate (less than 1% per year) when used consistently and correctly\n* Male patients must be using an effective form of contraception\n\nExclusion Criteria:\n\n* Knee Injections within the last 3 months (cortisone, PRP, hyaluronic acid)\n* Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)\n* Younger than 40 years of age\n* Older than 75 years of age\n* Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners\n* History of cannabis abuse or dependence\n* History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values\n* History of stroke or acute coronary syndromes within 3 months\n* Abnormal coagulation profile\n* Renal failure (serum creatinine \\> 250 μmol\u002FL \\[2.83 mg\u002FdL\\]) or liver cirrhosis\n* Patients that have been on opioid management for any reason just prior to the study\n* Patients with known inflammatory arthritis (such as rheumatoid arthritis, gout, pseudogout etc)\n* Patients with a large effusion\n* Patients with a BMI \\> 35\n* Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder\n* Patients diagnosed with major depression, psychosis, or substance abuse disorder\n* Patients with current or a history of suicidal ideation\n* Breastfeeding females\n* Abnormal LFTs\n* Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain\u002Fhead injury, or seizures\n* Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).\n* Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians\n* Patients taking strong CYP3A4 and CYP2C19 inducers (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians\n* Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians","40 Years","75 Years",{"count":122,"type":23},[196,300],"The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain, improve function, and improve patient satisfaction in cases of knee osteoarthritis. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a 'high' or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses.",[465],"Knee Arthritis",{"date":341,"type":34},{"date":468,"type":34},"2022-06-22",{"date":470,"type":23},"2027-09",{"name":40,"class":41},{"id":473,"slug":474,"hasResults":12,"nctId":475,"briefTitle":476,"officialTitle":476,"acronym":4,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":163,"enrollmentInfo":478,"targetDuration":4,"studyType":24,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":487,"leadSponsor":489,"locationsCount":42},"100370498","blood-flow-restriction-therapy-in-achilles-injury-100370498","NCT04104126","Blood Flow Restriction Therapy in Achilles Injury","Inclusion Criteria:\n\n* Diagnosed with Achilles Injury\n* Must be at least 18 years of age and younger than 65 years of age\n* Intention to receive physical therapy as standard of care\n\nExclusion Criteria:\n\n* Patients with intention to receive standard therapy and not the study therapy\n* Patients with impaired circulation, peripheral vascular compromise, previous revascularization of the extremity, or severe hypertension\n* Younger than 18 years of age or older than 65\n* Legally incompetent or mentally impaired (e.g. minors, Alzheimer's subjects, dementia, etc.)\n* Any patient considered a vulnerable subject",{"count":479,"type":23},57,[26],"Blood flow restriction (BFR) therapy is a brief and partial restriction of venous outflow of an extremity during low load resistance exercises. It is a safe and effective method of improving strength in healthy and active individuals, recovering from orthopedic pathologies and procedures. This prospective, randomized study will look at the implications this form of treatment has on the rehabilitation of Achilles injuries.",[483],"Achilles Injuries Tendon",{"date":389,"type":34},{"date":486,"type":34},"2021-10-08",{"date":488,"type":23},"2026-06-01",{"name":40,"class":41},{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":4,"eligibilityCriteria":496,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":497,"targetDuration":4,"studyType":24,"phases":499,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":42},"100383281","the-effect-of-yoga-practice-on-chronic-back-pain-100383281","NCT04270617","The Effect of Yoga Practice on Chronic Back Pain","A Prospective, Randomized-controlled Study to Evaluate the Effect of a Standardized Yoga Practice on Chronic Back Pain","Inclusion Criteria:\n\n* Willingness to and ability to participate in study procedures\n* Chronic back pain (pain above the gluteal cleft of at least 3 months duration)\n\nExclusion Criteria:\n\n* Indication for surgery (i.e., fracture, infection, scoliosis, spondylolisthesis)\n* Cardiac, pulmonary or other medical comorbidities that preclude participation in yoga practice",{"count":498,"type":23},200,[26],"Chronic low back pain is notoriously difficult to treat and is a primary contributor to lost work days and excessive health expenditures, and whose treatment has, in part, contributed to the opioid crisis. Surgery is only an option in a minority of these patients, usually confined to those with structural instability. Yoga is an ancient modality whose benefits are currently being studied.",[502],"Chronic Back Pain","2026-06-03",{"date":430,"type":34},{"date":506,"type":34},"2019-12-01",{"date":508,"type":23},"2028-01",{"name":40,"class":41},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":519,"conditions":520,"keywords":521,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":527,"startDateStruct":528,"completionDateStruct":529,"leadSponsor":530,"locationsCount":42},"100183383","risk-factors-for-sudden-unexplained-death-in-epilepsy-100183383","NCT01662453","Risk Factors for Sudden Unexplained Death in Epilepsy","Risk Factors for Sudden Unexplained Death in Epilepsy (SUDEP)","SUDEP","Inclusion Criteria Sudep Group Subjects diagnosed with epilepsy whose cause of death was sudden and unexplained, and whose families are willing to participate, will be included in the study.\n\nControl Group For the control group, we will include any patient diagnosed with epilepsy currently in the care of the NYU Comprehensive Epilepsy Center, willing and able to participate in the study.",{"count":355,"type":23},"The main purpose of this study is to develop a North American registry for SUDEP cases; requesting family members of epilepsy patients who died suddenly of unclear causes (SUDEP) to contact the study team. The family members who decide to participate in the study will be asked to complete a brief telephone interview about their loved one's epilepsy and seizure history and the circumstances of his or her death. If the death has occurred within the past 24 hours, and the family is willing to consider donating tissue to the study, the subject will be transferred to the Autism Tissue Program, and the remainder of the phone interview will be conducted at a later time.\n\nIn addition to the phone interview, the family will be asked to provide access to the deceased's medical records. Any costs involved in obtaining medical records will be covered by the study, and all medical information will remain completely confidential.",[516],[522,523,524,525,526],"epilepsy","seizures","mortality","sudep","risk factors",{"date":430,"type":34},{"date":369,"type":4},{"date":470,"type":23},{"name":40,"class":41},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":17,"sex":18,"minAge":538,"maxAge":539,"enrollmentInfo":540,"targetDuration":4,"studyType":145,"phases":4,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":547,"startDateStruct":548,"completionDateStruct":550,"leadSponsor":552,"locationsCount":42},"100093592","hirschsprung-disease-genetic-study-100093592","NCT00478712","Hirschsprung Disease Genetic Study","Genetic Analysis of Hirschsprung Disease","Inclusion Criteria:\n\n\\- Individuals with Hirschsprung disease and their first degree relatives (any segment length of disease, with or without other congenital anomalies or health problems, single or multiple affected individuals in family)\n\nExclusion Criteria:\n\n* Unable or unwilling to provide sample for genetic studies\n* Individual, parent, or guardian unable to comprehend and provide informed consent","1 Week","100 Years",{"count":541,"type":23},3000,"Hirschsprung disease is a genetic condition caused by lack of nerve cells in varying lengths of the intestines. This study will investigate the complex genetic basis of the disease, which involves multiple interacting genetic factors.",[544],"Hirschsprung Disease",[546],"Hirschsprung",{"date":430,"type":34},{"date":549,"type":34},"2001-01",{"date":551,"type":23},"2028-12",{"name":40,"class":41},""]